Breastfeeding is Safe After Treatment for BRCA-Positive Breast Cancer

Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the 2024 Annual meeting of the European Society for Medical Oncology, ESMO.  The Scientific Chair of the meeting, Rebecca Dent MD, Deputy Chief Executive Officer of the National Cancer Center in Singapore, told Oncology Times reporter Peter Goodwin about some of the key areas of progress covered by the meeting that she was most excited about.